ProQR Therapeutics (PRQR) Lifted to Hold at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a research note issued to investors on Tuesday.

PRQR has been the subject of several other reports. Royal Bank of Canada initiated coverage on shares of ProQR Therapeutics in a report on Wednesday, December 19th. They issued an outperform rating for the company. Cantor Fitzgerald set a $40.00 price objective on shares of ProQR Therapeutics and gave the company a buy rating in a report on Tuesday, January 29th. Zacks Investment Research upgraded shares of ProQR Therapeutics from a hold rating to a strong-buy rating and set a $20.00 price objective for the company in a report on Wednesday, January 9th. Citigroup initiated coverage on shares of ProQR Therapeutics in a report on Thursday, November 15th. They issued a buy rating and a $32.00 price objective for the company. Finally, HC Wainwright reiterated a buy rating and issued a $20.00 price objective on shares of ProQR Therapeutics in a report on Thursday, February 28th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $28.67.

NASDAQ PRQR opened at $15.03 on Tuesday. ProQR Therapeutics has a 52 week low of $2.90 and a 52 week high of $24.00. The company has a quick ratio of 11.39, a current ratio of 13.28 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $581.96 million, a price-to-earnings ratio of -11.65 and a beta of 0.63.

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in ProQR Therapeutics by 14.1% during the fourth quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 2,375 shares during the last quarter. FMR LLC lifted its stake in ProQR Therapeutics by 27.8% during the fourth quarter. FMR LLC now owns 1,081,366 shares of the biopharmaceutical company’s stock valued at $17,064,000 after purchasing an additional 235,053 shares during the last quarter. Millennium Management LLC acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $1,428,000. Legal & General Group Plc acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $1,057,000. Finally, Squarepoint Ops LLC acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $169,000. 59.69% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

NBT Bancorp  Upgraded at Zacks Investment Research
NBT Bancorp Upgraded at Zacks Investment Research
Tantalex Resources  Hits New 1-Year Low at $0.04
Tantalex Resources Hits New 1-Year Low at $0.04
ProQR Therapeutics  Lifted to Hold at BidaskClub
ProQR Therapeutics Lifted to Hold at BidaskClub
Prudential Short Duration High Yield FD  Sets New 12-Month High at $14.39
Prudential Short Duration High Yield FD Sets New 12-Month High at $14.39
MB Financial  Downgraded to Sell at Zacks Investment Research
MB Financial Downgraded to Sell at Zacks Investment Research
PAR Technology  Announces Quarterly  Earnings Results
PAR Technology Announces Quarterly Earnings Results


Leave a Reply

 
© 2006-2019 Zolmax.